Table 1.
Baseline patient and disease characteristics.
| N=30 | % or Median (q1, q3) | |
|---|---|---|
| Age at baseline | 30 | 61 (52, 68) |
| Male gender | 27 | 90% |
| Histology | ||
| Clear-Cell | 26 | 87% |
| Papillary | 2 | 7% |
| Unknown | 2 | 7% |
| Baseline sites of metastases | ||
| Lung | 17 | 57% |
| Lymph nodes | 18 | 60% |
| Bone | 10 | 33% |
| Liver | 9 | 30% |
| Brain | 5 | 17% |
| Baseline number of metastatic sites | ||
| 1 | 6 | 20% |
| >1 | 24 | 80% |
| Prior lines of systemic therapy | ||
| 1 | 15 | 50% |
| 2 | 8 | 27% |
| 3 | 3 | 10% |
| ≥4 | 4 | 13% |
| Time from original diagnosis to treatment | ||
| < 1 year | 25 | 83% |
| ≥1 year | 5 | 17% |
| ECOG performance status | ||
| 0 | 13 | 43% |
| 1 | 16 | 53% |
| Unknown | 1 | 3% |
| Hemoglobin (g/dL) | 30 | 11.9 (10.1, 13.7) |
| Corrected calcium (mg/dL) | 30 | 9.6 (9.4, 10.3) |
| IMDC risk group | ||
| Favorable | 2 | 7% |
| Intermediate | 17 | 57% |
| Poor | 10 | 33% |
| Unknown | 1 | 3% |
ECOG= Eastern Cooperative Oncology Group, IMDC=International Metastatic Renal Cell Carcinoma Database Consortium